Share This Article:

The Relationship between Mouth Squamous Cell Carcinoma (MSCC) with HPV Infection and the Presence of p53 & c-myc Mutation

Abstract Full-Text HTML Download Download as PDF (Size:831KB) PP. 939-943
DOI: 10.4236/jct.2013.45105    3,148 Downloads   4,738 Views   Citations

ABSTRACT


Introduction: Now the molecular epidemiology is a new experience. It’s was noted that ninety percent of mouth cancers are squamous cell carcinomas and recorded 0.96% year of all cancers in Indonesia. Human papilloma virus (HPV) was implicated in pathogenesis of cancer. As a remark, that mutations of p53 and c-myc are found 50% in cancer. Objective: Aims of this research were to know the relationship between the mouth squamous cell carcinoma (MSCC) with HPV infection, the presence of p53, and c-myc genes mutation. Methods and Material: Tissue biopsy frozen sections from Benign Mouth Squamous Cell (BMSC) and MSCC patients were collected from Mouth and Dental Department of Muwardi District Hospital in Solo—Indonesia. To amplify L1-HPV gene for fixed the HPV etiology, amplified p53 and c-myc genes continued with SSCP analysis and followed with measurement using densitometer to see mutation existence. The collected data were analyzed with Chi Square Test. Results: None of the sample of patients with BMSC with positive HPV showed p53 gene mutation or c-myc gene. From eleven samples obtained from patients with MSCC who were positive HPV showed 18.2% had mutations in the p53 gene and 9.1% had mutations in c-myc gene. The chisquare test was shown to have significant differences between the MSCC with HPV infection and the presence of p53 and c-myc genes mutation. Conclusion: HPV is a risk ingredient for MSCC.


Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Prayitno, E. Asnar and S. Putra, "The Relationship between Mouth Squamous Cell Carcinoma (MSCC) with HPV Infection and the Presence of p53 & c-myc Mutation," Journal of Cancer Therapy, Vol. 4 No. 5, 2013, pp. 939-943. doi: 10.4236/jct.2013.45105.

References

[1] R. Doll and R. Peto, “The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today,” Journal of the National Cancer Institute, Vol. 66, No. 6, 1981, pp. 1191-308.
[2] K. W. Kinzler and B. Vogelstein, “Introduction. The Genetic Basis of Human Cancer,” McGraw-Hill, Medical Publishing Division, New York, 2002, p. 5.
[3] National Cancer Institute, US National Institute of Health, “Evidence of Benefit,” 2009. http://www.cancer.gov/cancertopics/pdq/prevention/oral/HealthProfessional/page4
[4] R. I. Morimoto, “Regulation of the Heat Shock Transcriptional Response: Cross Talk between a Family of Heat Shock Factors, Molecular Chaperones, and Negative Regulators,” Genes & Development, Vol. 12, No. 24, 1998, pp. 3788-3796. doi:10.1101/gad.12.24.3788
[5] C. R. Young and C. J. Welsh, “Stress, Health, and Disease,” Cell Science, Vol. 2, No. 2, 2005, pp. 132-159.
[6] E. H. Vogel, M. E. Castro, P. A. Solar and F. A. Soto, “Enhancement of Pavlovian Conditioned Immunosuppression in Rats,” Acta Neurobiologiae Experimentalis, Vol. 67, No. 1, 2007, pp. 71-81.
[7] M. A. González Intxaurraga, R. Stankovic, R. Sorli and G. Trevisan, “HPV and Carcinogenesis,” Acta Dermatovenerologica, Vol. 11, No. 3, 2002, pp. 1-8.
[8] S, Choi and J. N. Myers, “Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy,” Journal of Dental Research, Vol. 87, No. 1, 2008, pp. 14-32. doi:10.1177/154405910808700104
[9] H. L. Schmits, “Species Diagnostics Protocols: PCR and Other Nucleic Acid Methods,” In: J. P. Clapp, Ed., Methods in Molecular Biology, Humana Press, Totowa, 1996, 416 pp.
[10] M. M. Nigel and F. Nina, “Typing of HPV Isolates by PCR: Molecular Approach toward Vaccine Development for Viral Infection,” Icro-Unesco Training Course, Inter University Center for Biotecnology, Gajah Mada University, Yogyakarta, 1998, pp. 18-28.
[11] T. Hessel, S. P. Dhital, R. Plank and D. Dean, “Immune Response to Chlamydial 60-Kilodalton Heat Shock Protein in Tears from Nepali Trachoma Patients,” Infection and Immunity, Vol. 69, No. 8, 2001, pp. 4996-5000. doi:10.1128/IAI.69.8.4996-5000.2001
[12] P. E. Petersen, “Oral Cancer Prevention and Control— The Approach of the World Health Organization,” 2008. www.elsevier.com/locate/oraloncology
[13] N. W. Johnson, S. Warnakulasuriya, E. Gupta, P. C. Dimba, M. Chindia, E. C. Otoh, R. Sankaranarayanan, J. Califano and L. Kowalski, “Global Oral Health Inequalities in Incidence and Outcomes for Oral Cancer: Causes and Solutions,” Advances in Dental Research, Vol. 23, No. 2, 2011, pp. 237-246. doi:10.1177/0022034511402082
[14] Cancer Research UK, “Oral Cancer—Risk Factors,” 2009. http://info.cancerresearchuk. org/cancerstats/types/oral/ riskfactors/index.htm
[15] R. Mehrotra and S. Yadav, “Oral Squamous Cell Carcinoma: Etiology, Pathogenesis and Prognostic Value of Genomic Alterations,” Indian Journal of Cancer, Vol. 43, No. 2, 2006, pp. 60-66. doi:10.4103/0019-509X.25886
[16] S. R. Schwartz, B. Yueh, J. K. Mc Dougall, J. R. Daling and S. M. Sswartz, “Human Papillomavirus Infection and Survival in Oral Squamous Cell Cancer: A PopulationBased Study,” Otolaryngology—Head and Neck Surgery, Vol. 125, No. 1, 2001, pp. 1-9. doi:10.1067/mhn.2001.116979
[17] R. Elin, P. Edward, H. Masayuki, P. Marshall, L. Mei and T. K. Karl, “Human Papillomavirus Type 16 and Squamous Cell Carcinoma of the Head and Neck,” Clinical Cancer Research, Vol. 8, No. 10, 2002, pp. 3187-3192.
[18] N. Termine, V. Panzarella, S. falaschini, A. Russo, D. Matranga, L. Lo Muzio and G. Campisi, “HPV in Oral Squamous Cell Carcinoma vs Head And Neck Squamous Cell Carcinoma Biopsies: A Meta-Analysis (1988-2007),” Oxford Journals Medicine Annals of Oncology, Vol. 19, No. 10, 2008, pp. 1681-1690. doi:10.1093/annonc/mdn372
[19] A. O. Robert, G. N. Nikolaos and J. S. John, “Screening the Non-High Risk Oral Cancer Patient—Part 1,” Oral Cancer Foundation, University of Maryland, Baltimore Dental School, Baltimore, OCF Inc. Copyright 2001-2009. http://oralcancerfoundation.org/dental/why_screening_works.htm
[20] A. P. Read and T. Strachan, “Chapter 18: Cancer Genetics,” In: T. Strachan and A. P. Read, Eds., Human Molecular Genetics, Wiley, New York, 1999.
[21] R. Cotterman, V. X. Jin, S. R. Krig, J. M. Lemen, A. Wey, P. J. Farnham and P. S. Knoepfler, “N-myc Regulates a Widespread Euchromatic Program in the Human Genome Partially Independent of Its Role as a Classical Transcription Factor,” Cancer Research, Vol. 68, No. 23, pp. 2008, 9654-9662.
[22] K. Milde-Langosch, K. Albrecht, S. Joram, H. Schlechte, M. Giessing and T. L?ning, “Presence and Persistence of HPV Infection and p53 Mutation in Cancer of the Cervix Uteri and the Vulva,” International Journal of Cancer, Vol. 63, No. 5, 1995, pp. 639-645. doi:10.1002/ijc.2910630507
[23] M. P. Mayer and B. Bukau, “Hsp70 Chaperones: Cellular Functions and Molecular Mechanism,” Cellular and Molecular Life Sciences, 2005, Vol. 62, No. 6, 2005, pp. 670-684. doi:10.1016/S0022-2143(97)90130-X
[24] R. S. Fife, B. T. Rougraff, C. Proctor and G. W. Sledge Jr., “Inhibition of Proliferation and Induction of Apoptosis by Doxycycline in Cultured Human Osteosarcoma Cells,” Journal of Laboratory and Clinical Medicine, Vol. 130, No. 5, 1997, pp. 530-534.
[25] P. F. Andrew, O. Rolf and H. Steven, “The Epigenetic Progenitor Origin of Human Cancer,” Nature Reviews Genetics, Vol. 7, No. 1, 2006, pp. 21-33.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.